BRIEF published on 09/02/2024 at 07:05, 5 days 18 hours ago Relief Therapeutics annonce la présentation des résultats de l'étude PKU GOLIKE au SSIEM 2024 Essai Clinique PKU GOLIKE THÉRAPEUTIQUE DE SECOURS SSIEM 2024 Phénylcétonurie
BRIEF published on 09/02/2024 at 07:05, 5 days 18 hours ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 5 days 18 hours ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 8 days 18 hours ago Relief Therapeutics publie ses résultats financiers du premier semestre 2024 et une mise à jour de l'entreprise Résultats Financiers Essais Cliniques Mise À Jour De L'entreprise Augmentation Des Revenus Réserves De Trésorerie
BRIEF published on 08/30/2024 at 07:05, 8 days 18 hours ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 8 days 18 hours ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 month 2 days ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
BRIEF published on 08/05/2024 at 07:05, 1 month 2 days ago Relief Therapeutics obtient jusqu'à 11 millions de dollars grâce aux ventes de redevances Développement Clinique Financement Non Dilutif Approbation De La FDA Thérapeutique De Soulagement Ventes De Redevances
PRESS RELEASE published on 08/05/2024 at 07:00, 1 month 2 days ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 2 months 10 days ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
Published on 09/07/2024 at 01:30, 23 hours 59 minutes ago Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements
Published on 09/07/2024 at 00:30, 1 day ago Cheech and Chong’s Global Holding Company Responds to California’s Proposed Emergency Hemp Ban
Published on 09/06/2024 at 23:15, 1 day 2 hours ago BluSky Carbon Announces Extension of Strategic Marketing Agreement
Published on 09/07/2024 at 14:00, 11 hours 29 minutes ago Litigation costs drive US liability claims by 57% over past decade, reveals Swiss Re Institute
Published on 09/06/2024 at 22:00, 1 day 3 hours ago Successful completion of preset purchase plan for the acquisition of Northern Data Group shares by CEO Aroosh Thillainathan
Published on 09/06/2024 at 18:45, 1 day 6 hours ago Molten Ventures Plc: POS-Transaction in Own Shares
Published on 09/06/2024 at 18:15, 1 day 7 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/06/2024 at 17:56, 1 day 7 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/06/2024 at 18:00, 1 day 7 hours ago Declaration of voting rights at the end of August 2024